403 related articles for article (PubMed ID: 18724393)
21. The evolution of hematopoietic SCT in myelodysplastic syndrome.
Kindwall-Keller T; Isola LM
Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532
[TBL] [Abstract][Full Text] [Related]
22. Reduced intensity versus full myeloablative stem cell transplant for advanced CLL.
Peres E; Braun T; Krijanovski O; Khaled Y; Levine JE; Yanik G; Kato K; Mineishi S
Bone Marrow Transplant; 2009 Nov; 44(9):579-83. PubMed ID: 19308041
[TBL] [Abstract][Full Text] [Related]
23. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen.
Anderlini P; Saliba R; Acholonu S; Okoroji GJ; Donato M; Giralt S; Andersson B; Ueno NT; Khouri I; De Lima M; Hosing C; Cohen A; Ippoliti C; Romaguera J; Rodriguez MA; Pro B; Fayad L; Goy A; Younes A; Champlin RE
Bone Marrow Transplant; 2005 May; 35(10):943-51. PubMed ID: 15806128
[TBL] [Abstract][Full Text] [Related]
24. Nonmyeloablative second transplants are associated with lower nonrelapse mortality and superior survival than myeloablative second transplants.
Hill BT; Bolwell BJ; Rybicki L; Dean R; Kalaycio M; Pohlman B; Tench S; Sobecks R; Andresen S; Copelan E
Biol Blood Marrow Transplant; 2010 Dec; 16(12):1738-46. PubMed ID: 20558313
[TBL] [Abstract][Full Text] [Related]
25. Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.
Remberger M; Mattsson J; Hassan Z; Karlsson N; LeBlanc K; Omazic B; Okas M; Sairafi D; Ringdén O
Bone Marrow Transplant; 2008 Feb; 41(4):399-405. PubMed ID: 17982493
[TBL] [Abstract][Full Text] [Related]
26. Double reduced-intensity allogeneic hematopoietic stem cell transplantation: a retrospective study from the SFGM-TC.
Bay JO; Cabrespine A; Faucher C; Tabrizi R; Bordigoni P; Berceanu A; Coiteux V; Renaud M; Mialou V; Robin M; Kuentz M; Chevallier P; Dhédin N; Huynh A; Garban F; Witz F; Buzyn A; De Revel T; Galambrun C; Deconinck E; Contentin N; François S; Gratecos N; Blaise D; Michallet M;
Biol Blood Marrow Transplant; 2012 Feb; 18(2):250-6. PubMed ID: 21745455
[TBL] [Abstract][Full Text] [Related]
27. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
28. Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant.
Vicente D; Lamparelli T; Gualandi F; Occhini D; Raiola AM; Ibatici A; Van Lint MT; Gobbi M; Miglino M; Clavio M; Risso M; Frassoni F; Bacigalupo A
Bone Marrow Transplant; 2007 Aug; 40(4):349-54. PubMed ID: 17589537
[TBL] [Abstract][Full Text] [Related]
29. Allogeneic myeloablative transplantation for patients aged 50 years and over.
Yanada M; Emi N; Naoe T; Sakamaki H; Iseki T; Hirabayashi N; Karasuno T; Chiba S; Atsuta Y; Hamajima N; Takahashi S; Kato S
Bone Marrow Transplant; 2004 Jul; 34(1):29-35. PubMed ID: 15156161
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic haematopoietic stem-cell transplantation with reduced intensity conditioning for advanced stage Hodgkin's lymphoma in Sweden: high incidence of post transplant lymphoproliferative disorder.
Johansson JE; Remberger M; Lazarevic VLj; Hallböök H; Wahlin A; Kimby E; Juliusson G; Omar H; Hägglund H
Bone Marrow Transplant; 2011 Jun; 46(6):870-5. PubMed ID: 20956959
[TBL] [Abstract][Full Text] [Related]
31. Long-term follow-up of allogeneic bone marrow transplantation for patients with chronic phase chronic myeloid leukemia prepared with a regimen consisting of cyclophosphamide, cytarabine and single-dose total body irradiation conditioning.
Zaretsky Y; Rifkind J; Lockwood G; Tsang R; Kiss T; Hasegawa W; Fyles G; Tejpar I; Loach D; Minden M; Messner H; Lipton JH
Bone Marrow Transplant; 2007 Sep; 40(5):423-30. PubMed ID: 17603516
[TBL] [Abstract][Full Text] [Related]
32. Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma.
Arora M; McGlave PB; Burns LJ; Miller JS; Barke JN; Defor TE; Weisdorf DJ
Bone Marrow Transplant; 2005 Jun; 35(12):1133-40. PubMed ID: 15834435
[TBL] [Abstract][Full Text] [Related]
33. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma.
Qazilbash MH; Saliba R; De Lima M; Hosing C; Couriel D; Aleman A; Roden L; Champlin R; Giralt SA
Cancer; 2006 Mar; 106(5):1084-9. PubMed ID: 16456814
[TBL] [Abstract][Full Text] [Related]
34. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents--a Berlin-Frankfurt-Münster group report.
Woessmann W; Peters C; Lenhard M; Burkhardt B; Sykora KW; Dilloo D; Kremens B; Lang P; Führer M; Kühne T; Parwaresch R; Ebell W; Reiter A
Br J Haematol; 2006 Apr; 133(2):176-82. PubMed ID: 16611309
[TBL] [Abstract][Full Text] [Related]
35. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.
Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS
Biol Blood Marrow Transplant; 2008 Jun; 14(6):658-63. PubMed ID: 18489991
[TBL] [Abstract][Full Text] [Related]
36. Second allografts for relapsed hematologic malignancies: feasibility of using a different donor.
Duus JE; Stiff PJ; Choi J; Parthasarathy M; Rodriguez T; Toor AA
Bone Marrow Transplant; 2005 Feb; 35(3):261-4. PubMed ID: 15558039
[TBL] [Abstract][Full Text] [Related]
37. Impact of chimaerism analysis and kinetics on allogeneic haematopoietic stem cell transplantation outcome after conventional and reduced-intensity conditioning regimens.
Michallet AS; Fürst S; Le QH; Dubois V; Praire A; Nicolini F; Thomas X; Rafii H; Gebuhrer L; Michallet M
Br J Haematol; 2005 Mar; 128(5):676-89. PubMed ID: 15725090
[TBL] [Abstract][Full Text] [Related]
38. Association of HMGB1 polymorphisms with outcome after allogeneic hematopoietic cell transplantation.
Kornblit B; Masmas T; Petersen SL; Madsen HO; Heilmann C; Schejbel L; Sengeløv H; Müller K; Garred P; Vindeløv L
Biol Blood Marrow Transplant; 2010 Feb; 16(2):239-52. PubMed ID: 19819342
[TBL] [Abstract][Full Text] [Related]
39. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
[TBL] [Abstract][Full Text] [Related]
40. Reduced-intensity conditioning regimen preserves thymic function in the early period after hematopoietic stem cell transplantation.
Jiménez M; Martínez C; Ercilla G; Carreras E; Urbano-Ispízua A; Aymerich M; Villamor N; Amézaga N; Rovira M; Fernández-Avilés F; Gaya A; Martino R; Sierra J; Montserrat E
Exp Hematol; 2005 Oct; 33(10):1240-8. PubMed ID: 16219547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
